Varicose Veins
Introduction
Varicose veins are a common manifestation of chronic venous disease, characterized by enlarged, twisted veins, most frequently observed in the lower extremities. This condition presents both cosmetic and medical concerns . This narrow definition could lead to an underestimation of disease prevalence and a misclassification of controls, where undiagnosed cases might have been included in the control group. Such misclassification could bias associations towards the null, potentially diminishing statistical power and obscuring genuine genetic links. [1] Furthermore, the lack of access to individual-level data in some analyses, particularly when relying on summary statistics from projects like the Neale Lab and Gene ATLAS, limited the ability to control for potential selection or sampling biases directly. [2] The "quick-and-dirty" approach to summary statistics generation, coupled with stringent SNP quality control that removed a large proportion of initial SNPs, further contributed to a potential loss of statistical power for detecting gene-disease associations. [2]
Generalizability and Confounding Factors
A significant limitation regarding generalizability stems from the study population being predominantly of White British ancestry, as specifically noted in the GWAS analyses. [1] This restricts the direct applicability of the findings to other populations, highlighting a need for further research across diverse ancestries to understand the full spectrum of genetic contributions to varicose veins globally. Moreover, while some studies adjusted for basic demographic factors like age and sex, the comprehensive role of environmental and lifestyle confounders remains a challenge. Factors such as body mass index (BMI), deep venous thrombosis (DVT), and other lifestyle elements were not always fully characterized or controlled across all analyses, or their distribution in case and control groups was unknown. [2] Limitations in characterizing these candidate variables could lead to unequal representation and potentially induce spurious associations or mask true effect modifications, impacting the overall understanding of gene-environment interactions. [2]
Statistical Inference and Replication Gaps
Despite the large sample sizes employed, particularly in the UK Biobank cohort, some analyses faced challenges in statistical inference and lacked a replication stage. The observed genomic inflation, while partly attributed to a polygenic signal in which SNP-heritability accounted for 28% of the population variance, suggests that other factors also contribute to disease susceptibility, leaving a proportion of heritability unexplained. [1] The absence of an independent replication stage in some genetic studies means that findings exceeding genome-wide significance were not externally validated, which can increase the risk of reporting false positive associations, despite rigorous internal filtering criteria. [2] This necessitates cautious interpretation of novel associations and emphasizes the importance of future independent studies to confirm these genetic determinants and further explore the missing heritability components.
Variants
Genetic variations play a significant role in the predisposition to varicose veins, influencing various biological pathways related to vascular integrity, inflammation, and blood pressure regulation. Several genes and their associated single nucleotide polymorphisms (SNPs) have been identified as key contributors to the development of this common vascular condition. These variants often affect genes involved in vascular development, remodeling, and the mechanical properties of blood vessels.
Among the most strongly associated genetic loci are those involving CASZ1 and PIEZO1. The gene CASZ1, a transcription factor critical for development, is notably linked to varicose veins through variants such as rs11121615, which shows one of the strongest associations identified in genome-wide association studies. [3] This variant and others in the region, including rs10864469, have been implicated in blood pressure regulation and demonstrate pleiotropic effects, showing positive correlations with predicted and fat-free mass of the legs and whole body, as well as basal metabolic rate. [3] Similarly, variants in the PIEZO1 gene, such as rs2911463, rs2002833, and rs2932690, are strongly associated with varicose veins. [3] PIEZO1 encodes a mechanosensory ion channel vital for detecting mechanical forces in the vascular system, and its disruption can lead to significant disorganization of the vascular architecture, highlighting its importance for mature vascular development and remodeling. [3]
Other crucial genes contributing to varicose vein risk include PPP3R1, STIM2, and NFATC2. The PPP3R1 gene, a regulatory subunit of calcineurin, has been prioritized for its role, with its expression found to be increased in varicose veins compared to normal veins. [2] This gene is also known to induce MCP-1 production, a chemokine that is elevated in varicose veins and contributes to inflammation and vascular remodeling. [2] The STIM2 gene, involved in calcium signaling, is believed to play a role in blood vessel remodeling, with variant rs28558138 linked to blood pressure, hypertension, and other vascular/heart problems. [2] Likewise, NFATC2, a transcription factor in the NFAT pathway, is a prioritized gene with a putative role in blood vessel remodeling and is part of a pathway that influences varicose vein disease. [3]
Further genetic influences come from genes like EBF1, HDAC7, and SLC12A2-DT. EBF1, a transcription factor, is a prioritized gene, and its variant rs11135046 has been linked to blood pressure and hypertension. [2] The HDAC7 gene encodes a histone deacetylase, an enzyme that modifies chromatin structure and influences gene expression, potentially impacting endothelial cell function and vascular integrity. Variant rs73107980 within the HDAC7 locus has been associated with platelet crit and is located near RAPGEF3, a gene that regulates vascular permeability and promotes vascular smooth muscle cell migration, suggesting a role in venous wall remodeling. [2] The SLC12A2-DT gene, a divergent transcript, may regulate SLC12A2, a sodium-potassium-chloride cotransporter crucial for maintaining fluid balance and influencing blood pressure, thereby indirectly affecting venous health through variants like rs6860245, rs6595799, and rs2250127.
Finally, other genes such as SLC19A2 - F5, NME7, and ATP1B1 also contribute to the complex genetic landscape of varicose veins. SLC19A2 encodes a thiamine transporter, essential for cellular metabolism, which can impact the metabolic health of vascular cells. The F5 gene (Factor V) is a critical component of the blood coagulation cascade, and variations like rs1894692 could influence thrombosis risk, a common comorbidity with varicose veins. [3] Genes like NME7 and ATP1B1, with variant rs144737447, are involved in processes such as cell motility, nucleotide metabolism, and ion transport, respectively. These functions are fundamental to maintaining vascular smooth muscle tone and endothelial barrier integrity, and their disruption by specific variants can contribute to venous dysfunction and the development of varicose veins.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs11121615 rs10864469 |
CASZ1 | appendicular lean mass varicose veins |
| rs2002833 rs2932690 rs2911463 |
PIEZO1 | varicose veins hematological measurement |
| rs7569914 rs2861819 |
PPP3R1 - CNRIP1 | body height varicose veins |
| rs28558138 | TBC1D19 - STIM2 | varicose veins |
| rs6860245 rs6595799 rs2250127 |
SLC12A2-DT | appendicular lean mass sex hormone-binding globulin measurement level of myocilin in blood Red cell distribution width varicose veins |
| rs11135046 rs1432679 |
EBF1 | breast carcinoma varicose veins |
| rs12625547 | NFATC2 | varicose veins Eczematoid dermatitis eosinophil count |
| rs56389811 rs11168245 rs73107980 |
HDAC7 | adult onset asthma asthma varicose veins systolic blood pressure |
| rs1894692 | SLC19A2 - F5 | pneumonia blood protein amount atrial fibrillation tissue factor pathway inhibitor amount endometriosis |
| rs144737447 | NME7, ATP1B1 | T-cell surface glycoprotein CD3 epsilon chain measurement thrombophilia blood coagulation disease encounter with health service deep vein thrombosis |
Defining Varicose Veins
Varicose veins are primarily understood as dilated, tortuous veins, often affecting the lower extremities. Operationally, for large-scale epidemiological and genetic studies, varicose veins are typically defined using standardized diagnostic codes from international classification systems, such as ICD-9 code 454* and/or ICD-10 code I-83*. [1] This approach allows for consistent identification of cases across diverse healthcare datasets, although it may under-represent the true incidence by excluding individuals who do not seek formal medical attention or whose condition is only self-reported. [1] Conceptually, varicose vein disease is recognized to have a significant genetic component, with heritability estimated to account for 28% of the population variance. [1]
Clinical Classification and Associated Terminology
The clinical presentation of varicose veins falls within the broader spectrum of chronic venous disease (CVD). Within this framework, varicose veins are often classified by grades C2-C4, which encompass primary varicose veins with or without signs of edema and/or skin changes. [4] Importantly, this classification specifically excludes more severe manifestations such as healed or active venous ulcers (C5/C6), which represent advanced stages of CVD. [4] Anatomically, varicose veins frequently affect the superficial great saphenous vein (vena saphena magna), often accompanied by varicosities in the short saphenous vein (vena saphena parva). [4] It is also crucial to differentiate varicose veins from related but distinct conditions like phlebitis, thrombophlebitis, and deep vein thrombosis (DVT), which are often excluded from studies focusing specifically on varicose vein disease . [1], [4]
Diagnostic and Research Criteria
Diagnostic criteria for varicose veins in clinical research settings often combine coded diagnoses with specific clinical exclusions. For instance, studies utilize ICD-9 (454*) and ICD-10 (I-83*) codes as the primary outcome measure for diagnosing varicose veins. [1] Concurrently, patient cohorts are refined by including only those with primary varicose veins exhibiting grades C2-C4 of chronic venous disease, while actively excluding individuals with acute deep vein thrombosis or advanced venous ulcers (C5/C6). [4] Beyond clinical assessment, measurement approaches in research involve comprehensive data collection on potential risk factors, including demographics, lifestyle behaviors, medical history, body mass index, systolic blood pressure, and leg bioimpedance. [1] Genetic research further identifies susceptibility by conducting genome-wide association studies (GWAS), where single nucleotide polymorphisms (SNPs) with a P-value less than 5×10−8 are considered statistically significant. [1]
Pathophysiology of Vein Wall Degeneration
Varicose veins (VVs) of the lower extremities represent a common manifestation of chronic venous disease, characterized by the pathological remodeling of the vascular wall and a subsequent loss of its tone. [2] The primary drivers behind this degeneration include alterations in hemodynamic forces, specifically a decrease in laminar shear stress and an increase in venous filling pressure, which disrupt the normal physiological environment of the veins. [2] These mechanical changes contribute to endothelial activation and a chronic inflammatory state within the vein wall, further exacerbating structural damage. [2] Such disruptions ultimately lead to the characteristic dilatation and tortuosity observed in varicose veins.
The integrity of the vein wall is critically dependent on the balanced regulation of the extracellular matrix (ECM). In varicose veins, there is a dysregulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), which are crucial for maintaining ECM homeostasis. [4] An imbalance favoring MMP activity can lead to excessive degradation of ECM components, compromising the structural integrity and elasticity of the vessel wall. [4] Additionally, hypoxia, a condition of reduced oxygen supply, is implicated in the development of varicose veins, further contributing to cellular dysfunction and pathological remodeling of the vascular wall. [5]
Molecular and Cellular Mechanisms of Vascular Dysfunction
At a molecular level, the cellular functions within the vein wall are significantly disrupted in varicose veins. Endothelial cells, which line the inner surface of blood vessels, become activated in response to altered hemodynamic forces and inflammation, leading to changes in their permeability and adhesion properties. [2] This activation promotes the expression of chemokines, which are signaling proteins that recruit inflammatory cells, thereby perpetuating the inflammatory cycle within the venous tissue. [6] Key biomolecules such as ion channels also play a crucial role; for instance, the mechanically activated ion channel PIEZO1 is essential for vascular development and may contribute to the vein's response to mechanical stress. [7]
Further cellular dysfunction involves the aberrant activity of potassium voltage-gated channels, with genes like KCNJ16 and KCNJ2 identified in associated loci, suggesting their potential role in vascular biology and venous dilatation. [4] KCNH8, a member of the human Elk K+ channel gene family, is also recognized for its involvement in regulating smooth muscle contraction and has been linked to varicose vein formation. [4] The RAPGEF3 gene, another candidate, regulates vascular permeability and promotes vascular smooth muscle cell migration, processes directly relevant to the pathogenesis of varicose veins. [2]
Genetic and Epigenetic Contributions
Varicose veins have a strong hereditary component, with epidemiological, family, and genetic association studies consistently indicating a significant genetic basis for their etiology. [1] Genome-wide association studies (GWAS) have identified several susceptibility loci and candidate genes, providing insights into the molecular players involved. Genes such as CASZ1, PIEZO1, PPP3R1, EBF1, STIM2, HFE, GATA2, NFATC2, and SOX9 have been revealed as potential candidates for functional studies and drug targets. [2] For example, SOX9 directly controls the transcription of COL2A1, which encodes an extracellular matrix component, highlighting its role in maintaining vein wall structure. [2]
Other genetic findings include linkage to the FOXC2 region on chromosome 16 [8] and a protective missense variant in GJD3 enriched in certain populations. [9] Additionally, GWAS have identified EFEMP1 and KCNH8 as susceptibility loci, with EFEMP1 potentially impacting cellular and extracellular matrix components through interactions with MMPs and TIMPs, affecting vein elasticity. [4] Beyond direct gene functions, epigenetic modifications, such as DNA methylation, also contribute to the disease by altering gene expression patterns. For instance, DNA methylation and gene expression profiling have identified MFAP5 as a regulatory driver of extracellular matrix remodeling in varicose vein disease. [10]
Systemic Implications and Risk Factors
While primarily affecting the lower extremities, varicose veins can have broader systemic implications and are associated with other health conditions. They are recognized as a risk factor for deep venous thrombosis (DVT), and there is evidence of shared familial susceptibility between venous thromboembolism and varicose veins. [11] The presence of varicose veins has also been linked to an increased risk of peripheral artery disease, suggesting a complex interplay between various vascular pathologies. [11] These systemic connections underscore that the biological processes underlying varicose veins are not isolated but can reflect broader vascular health issues.
Beyond genetic predispositions, several non-genetic risk factors contribute to the development and progression of varicose veins. These include increased age, female sex, the number of pregnancies, obesity, and occupations requiring prolonged standing. [2] These factors likely interact with the underlying genetic and molecular susceptibilities, influencing hemodynamic forces and exacerbating the inflammatory and degenerative processes within the vein walls. Understanding these multifactorial influences is crucial for a comprehensive biological perspective on varicose veins.
Genetic Predisposition and Gene Regulation
Varicose veins are influenced by genetic factors, as evidenced by large-scale genetic studies . Large-scale epidemiological studies have been instrumental in identifying established clinical risk factors, including advanced age, female sex, pregnancy, obesity, and a history of deep vein thrombosis (DVT). [1] Beyond these, factors such as education level and systolic blood pressure have also emerged as significant associations. [1] The comprehensive assessment of these risk factors is vital for diagnostic utility, enabling early identification and risk stratification of individuals who may be predisposed to developing varicose veins or experiencing disease progression, particularly in the absence of approved medical therapies for prevention. [1]
Associated Comorbidities and Prognostic Implications
The clinical relevance of varicose veins extends beyond their superficial presentation, involving significant prognostic implications due to associations with several serious comorbidities. Patients diagnosed with varicose veins demonstrate up to a five-fold increased risk for developing deep vein thrombosis (DVT). [1] Furthermore, research indicates an association between varicose veins and other vascular diseases, including peripheral arterial disease. [1] These findings highlight varicose veins not merely as a localized issue but as a potential indicator of broader systemic vascular health, necessitating careful monitoring and management. Understanding these comorbidities is crucial for guiding long-term patient care, allowing clinicians to implement proactive strategies to mitigate potential complications and address underlying vascular pathology. [1]
Genetic Insights and Personalized Approaches
Genetic research has substantially advanced the understanding of varicose vein susceptibility, revealing a considerable heritable component that accounts for approximately 28% of the population variance. [1] Genome-wide association studies (GWAS) have identified numerous genetic variants, including 855 novel single nucleotide polymorphisms (SNPs), which influence susceptibility to varicose veins. [1] Notably, height has been established as a causal risk factor through Mendelian randomization, suggesting long-term implications for both disease development and associated complications. [1] Specific genetic loci, such as EFEMP1, KCNH8, and a protective missense variant in GJD3, have also been implicated . [4], [9] These genetic insights offer promising avenues for personalized medicine, potentially improving risk stratification, guiding the selection of treatment strategies, and contributing to the development of targeted therapies based on an individual's genetic profile.
Frequently Asked Questions About Varicose Veins
These questions address the most important and specific aspects of varicose veins based on current genetic research.
1. My mom and grandma have varicose veins. Will I definitely get them too?
No, not definitely, but your risk is higher due to a strong genetic link. Genetic factors account for about 28% of the population's risk. You might inherit predispositions in genes like FOXC2 or PIEZO1 that affect vein function, making you more susceptible, but lifestyle choices can still influence whether they develop.
2. My job requires standing all day. Does that make my genes for varicose veins worse?
Yes, prolonged standing is a significant risk factor that interacts with your genetic predisposition. If you have inherited variants in genes related to vein wall strength, like FBN2 or COL2A1, the added pressure from standing can exacerbate this underlying genetic tendency, potentially worsening their development.
3. If varicose veins run in my family, can exercising regularly still prevent them?
Regular exercise can definitely help, even with a family history. While genetics contribute significantly, improving blood flow and strengthening vein walls through activity can counteract some genetic predispositions, such as issues with ion channel function (e.g., PIEZO1). It might not entirely prevent them if your genetic risk is high, but it can significantly delay onset or reduce severity.
4. I'm overweight. Is that why I have varicose veins, or is it my family's genes?
Both obesity and your genetic background are important factors. Obesity increases pressure on your veins, acting as a direct risk factor. However, you might also have inherited genetic variants in genes like EFEMP1 or KCNH8 that make your veins more fragile, and being overweight can then amplify this underlying genetic susceptibility.
5. Why do women seem to get varicose veins more often, especially after pregnancy?
Women are more susceptible due to hormonal factors and the physical stress of pregnancy. Hormonal changes can relax vein walls, and the increased blood volume and pressure during pregnancy add strain. This interacts with any genetic predisposition you might have, such as variants affecting vascular smooth muscle cell function, making veins more prone to dilating.
6. My friend has just a few, but mine are really bad. Is that genetic?
Yes, the severity of varicose veins can be strongly influenced by your unique genetic makeup. Different combinations of genetic variants, for example, in genes related to the strength of your vein walls like FBN2 or COL2A1, or those affecting ion channels like PIEZO1, can lead to varying degrees of vein weakness and disease progression.
7. I'm not of White British ancestry. Does my background affect my varicose vein risk?
Yes, your ancestry can influence your risk. Most large-scale genetic studies on varicose veins have focused predominantly on people of White British ancestry. This means the specific genetic risk factors identified might differ in other populations, and further research is needed to fully understand how your unique genetic background contributes.
8. If I have "bad genes" for varicose veins, is there anything I can do to overcome them?
While you can't change your genes, you can significantly influence how they affect you. Since genetics account for about 28% of the risk, focusing on modifiable lifestyle factors like maintaining a healthy weight, avoiding prolonged standing, and staying active can greatly reduce your risk or delay onset, even with a strong genetic predisposition.
9. My family has them. Should I get genetic testing to see my risk?
While genetic research has identified many genes linked to varicose veins, such as PIEZO1 and FOXC2, routine genetic testing for personal risk assessment isn't typically recommended yet. The field is still developing, aiming for future diagnostic tools. For now, understanding your family history and managing known lifestyle risk factors is most important.
10. Do varicose veins just happen because I'm getting older, or are my genes involved too?
Both age and genetics play crucial roles. While increased age is a significant risk factor as veins naturally weaken over time, your inherited genetic predispositions, accounting for about 28% of the risk, can accelerate or worsen this process. Genes affecting extracellular matrix integrity (like FBN2) or ion channel function (like KCNJ16) can make your veins more susceptible to age-related changes.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Fukaya, E. et al. "Clinical and Genetic Determinants of Varicose Veins." Circulation, vol. 138, no. 27, 2018, pp. 2869-2880.
[2] Shadrina, A. S. et al. "Varicose veins of lower extremities: Insights from the first large-scale genetic study." PLoS Genet, vol. 15, no. 5, 2019, e1008110.
[3] Fukaya, E. "Clinical and Genetic Determinants of Varicose Veins." Circulation, 2020.
[4] Ellinghaus, E. et al. "Genome-wide association analysis for chronic venous disease identifies EFEMP1 and KCNH8 as susceptibility loci." Sci Rep, vol. 7, 2017.
[5] Lim, C. S., et al. "Hypoxia-inducible factor pathway and diseases of the vascular wall." J Vasc Surg, vol. 58, no. 1, 2013, pp. 219–230.
[6] Lattimer, C. R., et al. "Are inflammatory biomarkers increased in varicose vein blood?" Clin Appl Thromb, vol. 22, no. 7, 2016, pp. 656–664.
[7] Li, J., et al. "Piezo1 integration of vascular architecture." Nature, vol. 554, no. 7692, 2018, pp. 329–334.
[8] Ng, M. Y. M., et al. "Linkage to the FOXC2 region of chromosome 16 for varicose veins in otherwise healthy, unselected sibling pairs." J Med Genet, vol. 42, no. 3, 2005, pp. 235–239.
[9] Helkkula, P. et al. "Genome-wide association study of varicose veins identifies a protective missense variant in GJD3 enriched in the Finnish population." Commun Biol, vol. 6, 2023.
[10] Smetanina, M. A., et al. "DNA methylation and gene expression profiling reveal MFAP5 as a regulatory driver of extracellular matrix remodeling in varicose vein disease." Epigenomics, vol. 10, no. 8, 2018, pp. 1103–1119.
[11] Chang, S. L. et al. "Association of varicose veins with incident venous thromboembolism and peripheral artery disease." JAMA, vol. 319, 2018, pp. 807–817.